These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8601996)

  • 1. From dendritic cells to tumour vaccines.
    Hamblin TJ
    Lancet; 1996 Mar; 347(9003):705-6. PubMed ID: 8601996
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
    Armstrong AC; Cheadle EJ; Hawkins RE
    BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic clonotypic vaccines.
    Schwartz RS
    N Engl J Med; 1992 Oct; 327(17):1236-7. PubMed ID: 1406797
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination as immunotherapy for B cell lymphoma.
    Schultze JL
    Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
    Gatza E; Okada CY
    J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines in lymphoma.
    Levy R
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract]   [Full Text] [Related]  

  • 7. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
    Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
    J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients.
    Engleman EG; Fong L
    Clin Immunol; 2003 Jan; 106(1):10-5. PubMed ID: 12584045
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel approaches to immunotherapy for B-cell malignancies.
    Brentjens RJ
    Curr Hematol Rep; 2005 Jan; 4(1):64-72. PubMed ID: 15610662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
    Int Rev Immunol; 1989; 4(4):251-70. PubMed ID: 2519929
    [No Abstract]   [Full Text] [Related]  

  • 11. Dendritic cells: potential role in cancer therapy.
    Engleman EG
    Cytotechnology; 1997; 25(1-3):1-8. PubMed ID: 9474803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCs in lymphoma--biology and therapeutic aspects.
    Schultze JL; Fiore F; von Bergwelt-Baildon M
    Cytotherapy; 2004; 6(2):138-47. PubMed ID: 15203990
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
    Qiu Y; Yun MM; Dong X; Xu M; Zhao R; Han X; Zhou E; Yun F; Su W; Liu C; Zhao H; Tong X; Gao J; Ouyang X; Yun S
    Cytotherapy; 2016 Jan; 18(1):91-8. PubMed ID: 26549382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of B-cell lymphoma using peptides. A novel concept.
    Lam KS
    West J Med; 1993 May; 158(5):475-9. PubMed ID: 8342262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies in the treatment of lymphoma.
    Leonard JP
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):210-1. PubMed ID: 16163182
    [No Abstract]   [Full Text] [Related]  

  • 16. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo.
    Flamand V; Sornasse T; Thielemans K; Demanet C; Bakkus M; Bazin H; Tielemans F; Leo O; Urbain J; Moser M
    Eur J Immunol; 1994 Mar; 24(3):605-10. PubMed ID: 8125131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotypic vaccination in B-cell malignancies.
    Bianchi A; Massaia M
    Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumor immune responses induced by idiotype-pulsed dendritic cells with cell-penetrating peptide vaccination in vivo].
    Chang JH; Shi YX; Zhiang XS; Jiang WQ; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):804-7. PubMed ID: 18396634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
    Marron TU; Ronner L; Martin PE; Flowers CR; Brody JD
    Immunotherapy; 2016 Nov; 8(11):1335-1346. PubMed ID: 27993085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.